Group 1 - The core point of the article is that CSPC Pharmaceutical Group (01093) has received approval from the National Medical Products Administration of China to conduct clinical trials for its drug Dupilumab Injection [1] - The product is a recombinant fully human monoclonal antibody targeting IL-4Rα and is a biosimilar to Dupixent, classified under Category 3.3 for therapeutic biological products [1] - The drug is intended for the treatment of moderate to severe atopic dermatitis in adults [1] Group 2 - The development of the product follows the relevant research guidelines for biosimilars [1] - Pharmaceutical and non-clinical research results indicate that the product is highly similar to the reference drug in terms of quality, safety, and efficacy, supporting the initiation of subsequent clinical studies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的度普利尤單抗注射液（「該產品」）已獲中華人民共和國國家藥品監督管理 局批准，可在中國開展臨床試驗。 該產品是一種靶向IL -4Rα的重組全人源單克隆抗體藥物，為達必妥®的生物類似藥，按照 治療用生物製品3.3類申報，適用於治療成人中重度特應性皮炎。 該產品的研發遵循生物類似藥相關研究指南。藥學及非臨床研究結果顯示，該產品與原研 參照藥在質量、安全性和有效性方面高度相似，支持開展後續臨床研究。 代表董事會 石藥集團有限公司 主席 蔡東晨 香港，2025年8月19日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 蔡 東 晨 先 ...

Group 1 - The core viewpoint of the articles highlights the successful transformation of Chinese pharmaceutical companies from generic drug production to innovative drug development, with companies like Heng Rui Medicine, Shi Yao Group, and Han Sen Pharmaceutical leading the way in international markets [1][2][3] - The transition from generic to innovative drugs has been facilitated by significant reforms in drug approval processes, reducing average review times from three years to 60 days, which has created a favorable environment for innovation [3][4] - Companies that were once heavily reliant on generic drugs, such as Heng Rui Medicine, have seen a substantial increase in innovative drug sales, with Heng Rui's innovative drug revenue reaching 14 billion yuan in 2024, accounting for over half of its total sales [3][4] Group 2 - The path of "generic to innovative" is not without challenges, as the industry faces high costs and low success rates in innovative drug development, with the average time to develop a new drug being ten years and costs exceeding 1 billion USD [8][9] - Companies like Jiahe Biopharmaceutical faced setbacks, such as the rejection of their PD-1 drug application, which resulted in significant financial losses after years of investment [8][9] - The cultural shift required for companies to transition from a generic drug mindset to an innovative drug approach is significant, as it involves embracing risk-taking and fostering a culture of innovation [9][10] Group 3 - The strategy of "using generics to support innovation" has been adopted by many companies, allowing them to leverage profits from generics to fund innovative drug research and development [6][7] - Companies like Aosaikang have successfully diversified their product lines, with a notable increase in revenue from oncology and chronic disease products, offsetting declines in their traditional digestive drug sales [6][7] - The collaboration between generic and innovative drug development is seen as a strategic resource reallocation, where the experience gained in generics can aid in the commercialization of innovative drugs [7][8]

Group 1 - The core viewpoint of the article highlights the recent stock performance of CSPC Pharmaceutical Group, which saw a decline of 2.75% to HKD 10.62 per share, with a trading volume of HKD 3.02 billion [1] - CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company focused on the production of finished drugs and active pharmaceutical ingredients, with a strategic emphasis on innovative drugs targeting various therapeutic areas including neurological diseases, oncology, anti-infection, and cardiovascular diseases [1] - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 70.15 billion and a net profit of HKD 14.78 billion [1] Group 2 - CSPC Pharmaceutical Group is scheduled to disclose its interim report for the fiscal year 2025 on August 22 [2]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Key Points - The top three companies with net inflows from southbound funds are Xinda Biopharmaceutical (01801) with 835 million, China Life (02628) with 403 million, and AIA Insurance (01299) with 373 million [1][2] - The top three companies with net outflows are the Tracker Fund of Hong Kong (02800) with -6.679 billion, Hang Seng China Enterprises (02828) with -2.584 billion, and Anta Sports (02020) with -782 million [1][2] - In terms of net inflow ratio, Canggang Railway (02169) leads with 66.05%, followed by Bosideng (03998) with 49.50%, and Zhengzhou Bank (06196) with 48.61% [1][2] - The companies with the highest net outflow ratios include Skyworth Group (00751) at -52.19%, Anta Sports (02020) at -50.20%, and Ruipu Lanjun (00666) at -44.79% [1][2] Net Inflow Rankings - The top ten companies by net inflow include: - Xinda Biopharmaceutical (01801) with 835 million and a closing price of 95.000 (+8.82%) [2] - China Life (02628) with 403 million and a closing price of 22.800 (+0.71%) [2] - AIA Insurance (01299) with 373 million and a closing price of 76.400 (+3.03%) [2] - Other notable companies include Ideal Automotive (02015) with 365 million and a closing price of 97.150 (+3.30%) [2] Net Outflow Rankings - The top ten companies by net outflow include: - Tracker Fund of Hong Kong (02800) with -6.679 billion and a closing price of 26.080 (+2.35%) [2] - Hang Seng China Enterprises (02828) with -2.584 billion and a closing price of 93.760 (+2.76%) [2] - Anta Sports (02020) with -782 million and a closing price of 90.000 (+0.22%) [2] - Other significant outflows include Alibaba (09988) with -267 million and a closing price of 123.700 (+6.09%) [2] Net Inflow Ratio Rankings - The top companies by net inflow ratio include: - Canggang Railway (02169) with 66.05% and a closing price of 1.310 (-0.76%) [3] - Bosideng (03998) with 49.50% and a closing price of 4.600 (+0.66%) [3] - Zhengzhou Bank (06196) with 48.61% and a closing price of 1.410 (-2.08%) [3] Net Outflow Ratio Rankings - The top companies by net outflow ratio include: - Skyworth Group (00751) with -52.19% and a closing price of 3.260 (+1.24%) [3] - Anta Sports (02020) with -50.20% and a closing price of 90.000 (+0.22%) [3] - Ruipu Lanjun (00666) with -44.79% and a closing price of 12.160 (+5.28%) [3]

Group 1 - The company has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. for SYH2086, covering development, production, and commercialization, with potential total payments of up to $2.075 billion, including an upfront payment of $120 million and milestone payments based on annual net sales [1] - SYH2086 is in the preclinical stage and has complete intellectual property rights, with expectations for significant growth in the weight loss and MASH fields following the licensing agreement [1] - The management anticipates potential upfront and milestone payments from ongoing negotiations for three other projects, including SYS6010 (EGFR-ADC), could total around $5 billion [1] Group 2 - The company continues to increase its R&D investment, with 2024 R&D expenses projected to reach ¥5.191 billion (up 7.5% year-over-year), accounting for 21.9% of its revenue from prescription drugs, which is industry-leading [2] - As of the end of Q1 2025, the company has 24 projects in critical II/III clinical phases and 9 projects under review for market approval, indicating a robust pipeline [2] - The company is expected to achieve multiple new drug approvals and data readouts throughout the year, maintaining a strong position in business development [2] Group 3 - The company is recognized as a leading domestic pharmaceutical firm with ample cash reserves, transitioning from traditional pharmaceuticals to innovation [2] - The net profit forecasts for 2025 and 2026 have been revised down to ¥4.92 billion and ¥5.25 billion, respectively, reflecting a decrease of 24.9% and 23.9% from previous estimates [2] - The current valuation is considered attractive due to the expected orderly market entry of significant products, maintaining a "buy" rating [2]

Core Viewpoint - The company reported a revenue of 1.05 billion RMB for the six months ending June 30, 2025, reflecting a year-on-year growth of 7.99% [1] - The net loss attributable to shareholders was 2.746 million RMB, a significant decline from a net profit of 137 million RMB in the same period last year [1] - The basic loss per share was 0.0020 RMB [1] Financial Performance - Revenue for the period reached 1.05 billion RMB, marking a 7.99% increase compared to the previous year [1] - The company experienced a net loss of 2.746 million RMB, contrasting with a net profit of 137 million RMB from the prior year [1] - Basic loss per share was reported at 0.0020 RMB [1]

Group 1 - The company reported a revenue of 1.05 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 7.99% [1] - The net loss attributable to shareholders was 2.746 million RMB, compared to a net profit of 137 million RMB in the same period last year [1] - The basic loss per share was 0.0020 RMB [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 石藥創新製藥股份有限公司 截至2025年6月30日止六個月之未經審核財務資料 按深圳證券交易所之相關規定，石藥集團有限公司（「本公司」）附屬公司石藥創新製藥股份有 限公司（「石藥創新」），其股份於深圳證券交易所創業板上市（ 股票代碼：300765 ））已於2025 年8月15日發佈其截至2025年6月30日止六個月的未經審核中期報告（「2025年中期報告」）於深 圳 證 券 交 易 所 網 站 資 訊 披 露 頁 面 http: / / www.szse.cn / disclosure / listed / notice / index.html 。 石藥創新之財務資料乃根據中國企業會計準則編製。 本 公 告 附 錄（「 附 錄 」）所 載 石 藥 創 ...